latest news releases from the newsroom
E Mobile Information Technologies, Inc.
E Mobile Subsidiary Acquires Spirit Rent-A-Car, Inc.
FORT LAUDERDALE, Fla., April 12, 2006 (PRIMEZONE) -- E Mobile Technologies (Pink Sheets:EMTK) today announced that its subsidiary, Best Rate Travel USA, Inc., acquired Spirit Rent-A-Car, Inc. to service leisure, business and local customers in the thriving South Florida tourist market.
Oaktree Capital Management, LLC
Oaktree Capital Management Issues Letter to the Board of Directors of Interep National Radio Sales, Inc.
LOS ANGELES, April 12, 2006 (PRIMEZONE) -- Today, Oaktree Capital Management, LLC ("Oaktree"), on behalf of certain funds managed by Oaktree (the "OCM Funds"), sent a letter to the Board of Directors of Interep National Radio Sales, Inc. (Pink Sheets:IREP) ("Interep" or the "Company") notifying the Board that the OCM Funds' offer to acquire all of the Company's outstanding common shares pursuant to a merger transaction for consideration of $1.10 in cash per share (the "OCM Offer") -- which represents a 439% premium to yesterday's closing price -- will expire at 5:00 pm EDT on Friday, April 21, 2006.
The Quaker Funds, Inc.
Quaker's Flagship Fund Surpasses $1 Billion in Assets
MALVERN, Pa., April 12, 2006 (PRIMEZONE) -- The Quaker Funds, Inc. today is proud to announce that its flagship fund, the Quaker Strategic Growth Fund, has surpassed the $1 billion mark in assets under management. This impressive achievement comes several months before two other Quaker milestones. The Quaker Funds, Inc. celebrates its 10-year anniversary in July, and November will mark a decade since the inception of the Quaker Strategic Growth Fund.
Seeger Weiss LLP
Seeger Weiss LLP Announces Investigation of Fosamax-Related Jaw Injuries -- MRK
NEW YORK, April 12, 2006 (PRIMEZONE) -- Seeger Weiss LLP announces that it is investigating claims against Merck & Co. (NYSE:MRK) for Fosamax-related injuries, including reports of osteonecrosis of the jaw. Fosamax, marketed by Merck, is indicated for the treatment and prevention of osteoporosis (thinning of the bones) in men and women. Recent studies, however, suggest a link between the use of bisphosphonates, such as Fosamax, and osteonecrosis of the jaw, also known as "jaw death." This condition is associated with the interference of the blood supply to the bone and the consequential damage that occurs. Osteonecrosis of the jaw can be extremely painful and may lead to additional complications, such as infection, breakdown of the jawbone, and ulcerations in the lining of the mouth. It is not known if ceasing the use of Fosamax can lower the risk of osteonecrosis of the jaw, as the bisphosphonate medications metabolize slowly and remain in the bones for many years. If you have taken Fosamax and experienced any of the aforementioned side-effects, please visit http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Fosamax-P76/ or call (877) 541-3273 to request a free evaluation.